CLINICAL_TRIALS ClinicalTrials.gov record update

Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04592237
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:45.129335+00:00
Published At: 2025-12-23T00:00:00+00:00
Record Updated At: 2025-12-23
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Aggressive Variant Prostate Carcinoma", "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Metastatic Prostate Neuroendocrine Carcinoma", "Metastatic Prostate Small Cell Carcinoma", "Stage IV Prostate Cancer AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-23"
protocolSection.identificationModule.nctId: "NCT04592237"
protocolSection.identificationModule.officialTitle: "Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.